[Remote] Regional Director, Medical Science Liaisons (East) at Arcellx

Remote

Apply Now

Not SpecifiedCompensation

N/AExperience Level

N/AJob Type

Not SpecifiedVisa

N/AIndustries

Requirements

Advanced scientific degree (PharmD, PhD, MD, or equivalent) strongly preferred
Master’s degree in health sciences considered with extensive relevant experience
5+ years of experience in biotech/pharma
2+ years of experience in field leadership
Demonstrated expertise in hematology and multiple myeloma; cell therapy or oncology experience strongly preferred
Proven ability to lead and develop distributed teams
Excellent communication, interpersonal, and strategic planning skills
Ability to travel extensively within region and occasionally for national meetings
Must live within the assigned region

Responsibilities

Recruit, coach, and manage a team of high-performing MSLs
Develop and execute territory plans in alignment with Medical Affairs strategies
Monitor territory coverage, scientific engagements, and metrics to optimize team impact
Lead regional implementation of the medical affairs plan
Partner with cross-functional departments to ensure alignment with company priorities
Oversee regional congress planning and ensure effective post-meeting insight dissemination
Maintain deep scientific and clinical knowledge of cell therapy, immuno-oncology, hematology, and multiple myeloma

Skills

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free